GlaxoSmithKline company has temporarily stopped nationwide production and distribution of “Excedrin Extra Strength” and “Excedrin Migraine,” after “inconsistencies in how we transfer and weigh ingredients,” was discovered according to a government affairs spokesman for the company.
Spokeswoman Kathleen Beatty said the company's production halt is leading to a shortage in NY, NJ and other areas on the country as shelves reserved for Excedrin are empty at big stores like Wegmans, Tops, Walmart and Walgreens, and locally owned pharmacies.
The following is a statement released by Kathleen Beatty, Communications and Government Affairs Spokeswoman GlaxoSmithKline:
“Patient safety and product quality are our utmost priorities at GSK. Through routine quality control and assurance measures, we discovered inconsistencies in how we transfer and weigh ingredients for Excedrin Extra Strength Caplets and Geltabs and Excedrin Migraine Caplets and Geltabs.
Based on the available data, GSK believes that the product does not pose a safety risk to consumers. However, as a precautionary measure, GSK Consumer Healthcare has voluntarily implemented a discontinuation of production and distribution.
We are working hard to resolve the issue as quickly as possible, but at this point in time cannot confirm a definite date as to when supply will resume.
Other Excedrin products are available along with other pain-relieving drugs, but dosages may differ. Consumers should consult their pharmacist for the most suitable alternative product.“
GlaxoSmithKline advises customers to consult their pharmacists for the best alternative.